GCA trial's new data indicates 56% of people treated with RoActemra achieved steroid-free disease remission

New data from giant-cell arteritis (GCA) trial indicates that 56% of people treated with RoActemra (tocilizumab) achieved steroid-free disease remission at one year, compared with only 14% given the present standard of care with steroids alone.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news